secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0000950170-24-103957
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto effectuates 1-for-25 reverse stock split effective August 29, 2024
--------------------------------------------------------------------------

- Stockholders approved reverse split at June 20 special meeting; board set ratio at 1-for-25.
- Every 25 pre-split shares converted into 1 share; fractional shares rounded up to whole share.
- Outstanding stock options and equity plans proportionately adjusted; trading symbol GLTO unchanged.
- New CUSIP number is 36322Q 206; split effective after market close on August 29, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017024103957/0000950170-24-103957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017024103957/glto-20240829.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-103957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer